SCHEMBL6347396

SCHEMBL6347396

C=CC/[C]=C/CCCCCC

nearest known ligand 0.56

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.56
ALDH1A1 P00352 1/20 0.42
ABCG2 Q9UNQ0 2/20 0.36
CACNA2D1 P54289 1/20 0.36
CACNB2 Q08289 1/20 0.36
CACNA1C Q13936 1/20 0.36
FAAH O00519 2/20 0.35
TRPV1 Q8NER1 1/20 0.35
PTGS1 P23219 1/20 0.35
PPARG P37231 1/20 0.35
OPRK1 P41145 1/20 0.35
THRB P10828 1/20 0.35
DNM1 Q05193 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7738560 1.00 TSHR (0.56) TSHRALDH1A1ABCG2CACNA2D1CACNB2
SCHEMBL1888612 0.98 TSHR (0.52) TSHRALDH1A1ABCG2CACNA2D1CACNB2
SCHEMBL3341875 0.91
SCHEMBL6336602 0.83 TRPV1 (0.47) ALDH1A1FAAHTRPV1PTGS1PPARG
SCHEMBL10880422 0.81
SCHEMBL9142379 0.79 TSHR (0.64) TSHRALDH1A1ABCG2FAAHTRPV1
SCHEMBL3499793 0.79 TSHR (0.64) TSHRALDH1A1ABCG2FAAHTRPV1
SCHEMBL4354065 0.79 TSHR (0.64) TSHRALDH1A1ABCG2FAAHTRPV1
SCHEMBL9140978 0.79 TSHR (0.64) TSHRALDH1A1ABCG2FAAHTRPV1
SCHEMBL9141366 0.79 TSHR (0.64) TSHRALDH1A1ABCG2FAAHTRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4906559-A Light-sensitive silver halide photographic material KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) 1990-03-06 US claimed
US-6911553-B1 Osteoblast-specific mitogens and drugs containing such compounds ROCHE DIAGNOSTICS GMBH (DE) 2005-06-28 US disclosed
US-20050014723-A1 Osteoblast-specific mitogens and drugs containing such compounds ESSWEIN ANGELIKA (DE) 2005-01-20 US disclosed
EP-1019062-B1 OSTEOBLAST-SPECIFIC MITOGENS AND DRUGS CONTAINING SUCH COMPOUNDS ROCHE DIAGNOSTICS GMBH (DE) 2003-02-05 EP disclosed
US-6444832-B1 OSTEOPOROSIS ESSWEIN ANGELIKA (DE) 2002-09-03 US disclosed
US-6337170-B1 DYE CONCENTRATION, IMAGE FASTNESS FUJI PHOTO FILM CO., LTD. (JP) 2002-01-08 US disclosed
EP-0865422-B1 USE OF AMINOALCOHOLDERIVATIVES AS DRUGS, DERIVATIVES AND PROCESS FOR THEIR PREPARATION ROCHE DIAGNOSTICS GMBH (DE) 2001-07-11 EP disclosed
US-6197759-B1 ADMINISTERING LYSOPHOSPHATIDYLIC ACID DERIVATIVE ROCHE DIAGNOSTICS GMBH (DE) 2001-03-06 US disclosed
EP-0906759-A1 Novel osteoblastic specific mitogenes: process for their preparation and drugs containing these compounds Roche Diagnostics GmbH (DE) 1999-04-07 EP disclosed
US-4906559-A Light-sensitive silver halide photographic material KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) 1990-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014723-A1 Osteoblast-specific mitogens and drugs containing such compounds LPAR1, LPAR2, LPAR4 TSHR 2249/4885ALDH1A1 1997/4885ABCG2 2239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.